Yanli Li1, Zandra Klippel2, Xiaolong Shih3, Maureen Reiner4, Hong Wang5, John H Page6. 1. Center for Observational Research, Amgen Inc., 1150 Veterans Blvd, South San Francisco, CA, 94080, USA. yanli.li@amgen.com. 2. Hematology/Oncology, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA, 91320, USA. 3. SimulStat Incorporated, 4370 La Jolla Village Dr, San Diego, CA, 92122, USA. 4. Global Biostatistical Science, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA, 91320, USA. 5. TechData Service Company, LLC, 700 American Avenue, King of Prussia, PA, 19406, USA. 6. Center for Observational Research, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA, 91320, USA.
Abstract
PURPOSE:Chemotherapy-induced neutropenia (CIN) may increase infection risk for cancer patients; however, there is limited understanding on the quantitative relationships between severity and duration of CIN and infection risk. METHODS: This study combined individual data from adult cancer patients receiving no granulocyte colony-stimulating factor during the first chemotherapy cycle in six trials. We used area over the curve (AOC) of absolute neutrophil count (ANC) time-response curve (below different thresholds) to measure the combined effect of severity and duration of CIN. Time-dependent Cox proportional hazards models quantified the hazard of first infection associated with duration of grade 4 or grade 3/4 CIN and the hazard associated with AOC. RESULTS: We analyzed data from 271 patients who had small cell lung cancer, non-Hodgkin's lymphoma, head and neck cancer, or breast cancer; 63.8 % of the patients had advanced cancer, and 77.5 % received chemotherapy regimens with high risk of febrile neutropenia. In the first cycle, 18.8 % of the patients had infection-related hospitalizations. Each additional day patients had grade 3/4 or grade 4 CIN was associated with 28 % (95 % CI 7, 51 %) and 30 % (95 % CI 10, 54 %) increased risk of infection-related hospitalization, respectively. Each unit increase in AOC (day × 10(9)/L ANC), with threshold of ANC < 0.5 × 10(9)/L, was associated with a significantly increased risk of infection-related hospitalization (hazard ratio 1.98; 95 % CI 1.35, 2.90). CONCLUSIONS:Infection risk increases dramatically with each additional day of grade 3 or 4 CIN. Interventions limiting CIN severity and duration are of critical importance to reduce infection risk in cancer patients receiving chemotherapy.
RCT Entities:
PURPOSE: Chemotherapy-induced neutropenia (CIN) may increase infection risk for cancerpatients; however, there is limited understanding on the quantitative relationships between severity and duration of CIN and infection risk. METHODS: This study combined individual data from adult cancerpatients receiving no granulocyte colony-stimulating factor during the first chemotherapy cycle in six trials. We used area over the curve (AOC) of absolute neutrophil count (ANC) time-response curve (below different thresholds) to measure the combined effect of severity and duration of CIN. Time-dependent Cox proportional hazards models quantified the hazard of first infection associated with duration of grade 4 or grade 3/4 CIN and the hazard associated with AOC. RESULTS: We analyzed data from 271 patients who had small cell lung cancer, non-Hodgkin's lymphoma, head and neck cancer, or breast cancer; 63.8 % of the patients had advanced cancer, and 77.5 % received chemotherapy regimens with high risk of febrile neutropenia. In the first cycle, 18.8 % of the patients had infection-related hospitalizations. Each additional day patients had grade 3/4 or grade 4 CIN was associated with 28 % (95 % CI 7, 51 %) and 30 % (95 % CI 10, 54 %) increased risk of infection-related hospitalization, respectively. Each unit increase in AOC (day × 10(9)/L ANC), with threshold of ANC < 0.5 × 10(9)/L, was associated with a significantly increased risk of infection-related hospitalization (hazard ratio 1.98; 95 % CI 1.35, 2.90). CONCLUSIONS:Infection risk increases dramatically with each additional day of grade 3 or 4 CIN. Interventions limiting CIN severity and duration are of critical importance to reduce infection risk in cancerpatients receiving chemotherapy.
Entities:
Keywords:
Area over the curve; Chemotherapy-induced neutropenia; Infection; Infection-related hospitalization
Authors: Michelle Shayne; Jeffrey Crawford; David C Dale; Eva Culakova; Gary H Lyman Journal: Breast Cancer Res Treat Date: 2006-05-17 Impact factor: 4.872
Authors: Gary H Lyman; David C Dale; Jonathan Friedberg; Jeffrey Crawford; Richard I Fisher Journal: J Clin Oncol Date: 2004-09-20 Impact factor: 44.544
Authors: Ruth Pettengell; Matthias Schwenkglenks; Robert Leonard; André Bosly; Robert Paridaens; Manuel Constenla; Thomas D Szucs; Christian Jackisch Journal: Support Care Cancer Date: 2008-03-20 Impact factor: 3.603
Authors: V Trillet-Lenoir; J Green; C Manegold; J Von Pawel; U Gatzemeier; B Lebeau; A Depierre; P Johnson; G Decoster; D Tomita Journal: Eur J Cancer Date: 1993 Impact factor: 9.162
Authors: Jeffrey Crawford; David C Dale; Nicole M Kuderer; Eva Culakova; Marek S Poniewierski; Debra Wolff; Gary H Lyman Journal: J Natl Compr Canc Netw Date: 2008-02 Impact factor: 11.908
Authors: Edgardo Rivera; M Haim Erder; Moshe Fridman; Debra Frye; Gabriel N Hortobagyi Journal: Breast Cancer Res Date: 2003-06-20 Impact factor: 6.466
Authors: Luis Malpica; Bolanle Mufuka; Jonathan Galeotti; Xianming Tan; Natalie Grover; Stephen M Clark; Anne Beaven; Hyman Muss; Christopher Dittus Journal: Leuk Lymphoma Date: 2020-02-09
Authors: Kai Rejeski; Ariel Perez; Pierre Sesques; Eva Hoster; Carolina Berger; Liv Jentzsch; Dimitrios Mougiakakos; Lisa Frölich; Josephine Ackermann; Veit Bücklein; Viktoria Blumenberg; Christian Schmidt; Laurent Jallades; Boris Fehse; Christoph Faul; Philipp Karschnia; Oliver Weigert; Martin Dreyling; Frederick L Locke; Michael von Bergwelt-Baildon; Andreas Mackensen; Wolfgang Bethge; Francis Ayuk; Emmanuel Bachy; Gilles Salles; Michael D Jain; Marion Subklewe Journal: Blood Date: 2021-12-16 Impact factor: 22.113
Authors: Justin G Horowitz; Gerard W Gawrys; Grace C Lee; Brittney A Ramirez; Carole M Elledge; Paul J Shaughnessy Journal: Transpl Infect Dis Date: 2021-07-30
Authors: Sibylle Schirm; Christoph Engel; Sibylle Loibl; Markus Loeffler; Markus Scholz Journal: J Cancer Res Clin Oncol Date: 2017-11-04 Impact factor: 4.553